MDXG (MiMedx Group) Inventories, Finished Goods: $20.9 Mil (As of Mar. 2026)


MDXG MiMedx Group Inc MDXG
53 GF Score
Price $4.08
GF Value $6.87
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Inventories, Finished Goods?

MiMedx Group MDXG +3.04% 53 Inventories, Finished Goods is $20.9 Mil as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 53/100 and a GF Value™ of $6.87 (Significantly Undervalued). The stock has 2 warning signs investors should review.

MiMedx Group's quarterly finished goods declined from Sep. 2025 ($19.3 Mil) to Dec. 2025 ($15.5 Mil) but then increased from Dec. 2025 ($15.5 Mil) to Mar. 2026 ($20.9 Mil).

MiMedx Group's annual finished goods increased from Dec. 2023 ($11.7 Mil) to Dec. 2024 ($14.2 Mil) and increased from Dec. 2024 ($14.2 Mil) to Dec. 2025 ($15.5 Mil).

MiMedx Group Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for MiMedx Group's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group Inventories, Finished Goods Chart

MiMedx Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.91 5.52 11.68 14.22 15.45

MiMedx Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.40 19.29 19.34 15.45 20.94
MDXG
53GF Score
MiMedx Group Inc MDXG
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $20.9 Mil mean?
MiMedx Group (MDXG) has a Inventories, Finished Goods of $20.9 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's Inventories, Finished Goods too high?
MiMedx Group's current Inventories, Finished Goods is $20.9 Mil. Overall, MiMedx Group has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Inventories, Finished Goods compare to MNPR and FTH?
MiMedx Group's Inventories, Finished Goods of $20.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on MiMedx Group and its competitors. MiMedx Group's current Inventories, Finished Goods is $20.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.87, compared to a current price of $4.08 — trading 40.6% below its estimated fair value. The current Inventories, Finished Goods is $20.9 Mil. MiMedx Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Inventories, Finished Goods is $20.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.08 is trading 40.6% below its estimated GF Value™ of $6.87. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Inventories, Finished Goods: $20.9 Mil
  • GF Value™: $6.87 vs. price of $4.08 (40.6% below fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
53GF Score

Get the complete analysis for MDXG

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.08
Price
$6.87
GF Value